Denmark· DK-28107313925
Arupsan
A eslicarbazepine product containing eslicarbazepinacetat, registered in Denmark by Abacus Medicine A/S. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Eslicarbazepine is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AF04 (eslicarbazepine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Eslicarbazepine · ATC N03AF04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of eslicarbazepine costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $2.32 in Italy to $4.08 in Switzerland — a ×1.8 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Eslicarbazepine · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$4.08
- ES Spain$3.49
- IT Italy$2.32
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Eslicarbazepinacetat
- Manufacturer
- Abacus Medicine A/S
- Country
- Denmark (DK)
- ATC code
- N03AF04
- ATC class
- Eslicarbazepine
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107313925
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
188 interactions on record for eslicarbazepine.
Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eslicarbazepine · interactions on record
188 records
- 17 severe
- 166 moderate
- 5 minor
Most severe, free to view
- Levonorgestrel and ethinylestradiolG03AA07severe
- Desogestrel and ethinylestradiolG03AA09severe
- Drospirenone and ethinylestradiolG03AA12severe
- EthinylestradiolG03CA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N03AF04
Eslicarbazepine, as other registers publish it.
- United StatesAptiomSumitomo Pharma America, Inc.
- United StatesAptiomSumitomo Pharma America, Inc.
- United StatesAptiomSumitomo Pharma America, Inc.
- United StatesAptiomSumitomo Pharma America, Inc.
- CanadaAPTIOMSUMITOMO PHARMA CANADA, INC.
- CanadaAPTIOMSUMITOMO PHARMA CANADA, INC.
- CanadaAPTIOMSUMITOMO PHARMA CANADA, INC.
- CanadaAPTIOMSUMITOMO PHARMA CANADA, INC.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd6c81a4-1b4b-43dc-87c6-5d4b8eb58343 GET /v1/drugs/fd6c81a4-1b4b-43dc-87c6-5d4b8eb58343?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "tabletter",
"source": "dkma",
"strength": "800 mg",
"auth_role": "DKMA",
"dk_drugid": "28107313925",
"substance": "Eslicarbazepinacetat",
"auth_procedure": "Par-Imp",
"in_medicinpriser": true,
"registration_date_serial": "45756"
}See everything about eslicarbazepine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.